Anti-C1q antibodies are a promising marker for the diagnosis and management of lupus nephritis. Immunological tests can differentiate proliferative from non-proliferative lupus nephritis, but anti-C1q ...

A case of lupus nephritis in a patient with chronic HCV This study reports the long-term renal outcomes of kidney biopsies performed at prespecified intervals to determine the safety and accuracy of ...

Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...

CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on January 22, 2026, Health Canada has approved Gazyva® (obinutuzumab) for ...

The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Meta-analysis revealed an overall 35.9% incidence of at ...

Eventual tapering and withdrawal of steroids in patients with lupus nephritis is recommended to minimize the drugs' adverse effects, but the ideal timing is uncertain. This study followed 136 lupus ...

Returning from the 2024 ACR Convergence, Dr Askanase highlights the presentation of the new 2024 American College of Rheumatology guidelines for lupus nephritis as the most impactful session at this ...

NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Roche's Gazyvaro, a drug that can restore kidney function in people living with lupus nephritis, has been cleared for use by ...